Johnson & Johnson Acquires Firefly, Partners with Sail; Lowers 2026 EPS

What Happened
Johnson & Johnson (filed July 29, 2026) announced it completed the acquisition of Firefly Bio, Inc. and entered strategic agreements and a collaboration with Sail Biomedicines. The two transactions together are expected to reduce the company’s 2026 adjusted operational EPS and adjusted EPS by approximately $0.64. The company updated its full-year 2026 guidance accordingly.

Key Details

• Total expected 2026 EPS impact: decrease of ~$0.64 (approximately $0.46 from Firefly; ~$0.18 from Sail).
• Updated 2026 guidance (midpoints):
  • Operational sales: $100.6B (range $100.3B–$100.9B).
  • Estimated reported sales: $101.1B (range $100.8B–$101.4B).
  • Adjusted operational EPS midpoint: $10.94 (prior midpoint $11.58) — decrease $0.64.
  • Adjusted EPS midpoint: $11.04 (prior midpoint $11.68) — decrease $0.64.
• Adjusted pre-tax operating margin: shift from an expected increase ~75 basis points vs. prior year to a decrease of ~75 basis points (net change ~150 bps).
• Currency effect on EPS: ~$0.10 benefit (0.9%), unchanged from prior guidance.
• 2027 outlook: combined transactions expected to reduce 2027 adjusted operational EPS and adjusted EPS by ~ $1.36 (Firefly ~$0.08; Sail ~$1.28), assuming Sail achieves certain development milestones and optional company actions.
• The company attached press releases for the Firefly acquisition and the Sail collaboration to the 8-K (Exhibits 99.1 and 99.2).

Why It Matters
For investors, these deals signal J&J’s continued business development in biotech but come with near-term dilution to adjusted EPS: a ~$0.64 hit to 2026 and an estimated larger hit to 2027 if milestones are met. Reported and operational sales guidance is largely maintained around $100–101B, so top-line expectations are stable while adjusted profitability is reduced. Note J&J’s updated figures use non-GAAP measures and the company did not provide GAAP reconciliations for forward-looking metrics; forward-looking statements are subject to risks and may change.